Race Oncology (ASX:RAC) received approval from the Bellberry Human Research Ethics Committee to start its RC220 Phase 1 clinical trial at Gosford and Wyong hospitals in New South Wales, according to a Monday filing with the Australian bourse.
The clinical research organization now expects to obtain final site approvals and activation by April, the filing said. Patient enrollment will start once these approvals are received. Human ethics approval for additional trial sites in Australia, Hong Kong, and South Korea is expected in the coming months.
The RAC-010 clinical trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 alone and in combination with doxorubicin in patients with solid tumors, the filing stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.